助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   acute ischaemic stroke 的翻译结果: 查询用时:0.01秒
图标索引 在分类学科中查询
所有学科
中医学
急救医学
神经病学
更多类别查询

图标索引 历史查询
 

acute ischaemic stroke
相关语句
  缺血性中风
     To determinately evaluate efficacy and safety of shengmai injection for acute ischaemic stroke,more rationally designed and strictly executed RCTs with large samples are necessary.
     要进一步验证生脉注射液治疗缺血性中风急性期的疗效及安全生,尚需进行设计合理、执行严格、多中心大样本且随访时间足够的随机对照试验。
短句来源
     Method: Strictly according to follow the method of systematic review, collect completely the clinic study of TCM for acute ischaemic stroke, choose the eligibility studies and appraise their quality, collect the data of the studies, make Meta-analyse, funnel plots and tests for heterogeneity.
     方法:严格按照循证医学系统评价方法,全面收集运用活血化瘀方药治疗缺血性中风急性期的临床研究文献,并按照文献选择标准进行筛选:采用Jadad评分标准评价纳入研究质量; 采集相关数据进行同质性检验、Meta-分析、漏斗图分析及敏感性分析等。
短句来源
     Methods: Randomized controlled trails(RCTs)of decoction in Nigorating yang for recuperation for acute ischaemic stroke were identified,eligible studies were included,the methodological quality of inclusive trails was assessed by Jadad scale.
     方法:检索补阳还五汤治疗缺血性中风急性期的随机对照试验文献,筛选合格研究,应用Jadad评分法进行质量评价,运用异质性检验、Meta-分析、敏感性分析、漏斗图分析等方法统计相关数据。
短句来源
     Objective: To systematically evaluate efficacy and safety of puerarin for treating acute ischaemic stroke.
     目的:系统评价葛根素治疗缺血性中风急性期的疗效及安全性。
短句来源
     Objective: To evaluate efficacy and safety of safflower injection for acute ischaemic stroke.
     目的:系统评价红花注射液治疗缺血性中风急性期的疗效及安全性。
短句来源
更多       
  急性缺血性卒中
     CD11c/CD18 and acute ischaemic stroke
     CD11c/CD18与急性缺血性卒中
短句来源
     Specific DWI lesion patterns predict prognosis after acute ischaemic stroke within the MCA territory
     特定DWI病损形式预测MCA供血区域急性缺血性卒中的预后
短句来源
     The role of high-sensitivity C-reactive protein (hs-CRP) levels in acute ischaemic stroke
     超敏C反应蛋白在急性缺血性卒中中的应用
短句来源
     Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study
     80岁以上急性缺血性卒中患者的血栓溶解:加拿大阿替普酶治疗卒中疗效研究
短句来源
     Significant variation in mortality and functional outcome after acute ischaemic stroke between western countries: Data from the tinzaparin in acute ischaemic stroke trial (TAIST)
     西方各国急性缺血性卒中后死亡率和功能性预后的显著差异:来自亭扎肝素治疗急性缺血性卒中试验(TAIST)的资料
短句来源
更多       
  “acute ischaemic stroke”译为未确定词的双语例句
     Repinotan is a highly potent and selective 5-HT_(1A) receptor full agonist developed by Bayer Corporation in USA. It is a putative neuroprotective compound in acute ischaemic stroke and traumatic brain injury.
     Repinotan是拜尔公司开发的一个具有高结合亲合力、高选择性的5-HT_(1A)受体完全激动剂,是公认的神经保护剂。
短句来源
     Evaluation of Shuxuetong injection for acute ischaemic stroke.
     疏血通注射液治疗缺血性脑卒中急性期随机对照试验的系统评价
短句来源
     To determinately evaluate efficacy and safety of tongxinluo capsule for acute ischaemic stroke,more rationally designed and strictly executed RCTs with large samples are necessary.
     要进一步验证通心络胶囊治疗缺血性卒中急性期的疗效及安全性,尚需进行设计合理、执行严格、多中心、大样本且随访时间足够的随机对照试验。
短句来源
     Measures: 58 patients at Shangdong Provincial Hospital with acute ischaemic stroke presenting less than 24 hours after symptom onset were incorporated into the study.
     方法 58例急性缺血性脑血管病病人及50例健康对照者来自山东省立医院,均于出现症状24小时内入组。
短句来源
     Thrombolytic therapy has not only been used as a routine approach in treatment of acute my-ocardial infarction, but also been used in other thromboembolic diseases, such as acute ischaemic stroke, pulmonary embolism, acute peripheral arterial thrombosis and so on.
     溶栓疗法不仅已被常规地用于急性心肌梗死的治疗,而且也已用于其它血栓病的治疗中,如急性缺血性脑血栓、肺栓塞、急性周围动脉血栓等。
短句来源
更多       
查询“acute ischaemic stroke”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  acute ischaemic stroke
Our previous work has demonstrated that angiogenesis occurs in the damaged brain tissue of patients surviving acute ischaemic stroke and increased microvessel density in the penumbra is associated with longer patient survival.
      
Accumulating data suggest that matrix metalloproteinases (MMPs), in particular MMP-2 and MMP-9, are deleterious after acute ischaemic stroke.
      
Early phase combined therapeutic management of acute ischaemic stroke
      
Therapeutic options dramatically increased both in the prevention and overall in the treatment of acute ischaemic stroke (AIS).
      
Inadequate blood supply relative to metabolic demand, a haemodynamic condition termed as misery perfusion, often occurs in conjunction with acute ischaemic stroke.
      
更多          


Thrombolytic therapy has not only been used as a routine approach in treatment of acute my-ocardial infarction, but also been used in other thromboembolic diseases, such as acute ischaemic stroke, pulmonary embolism, acute peripheral arterial thrombosis and so on. Prourokinase is the single-chain precursor of two-chain urokinase. It activates plasminogen preferentially at the fibrin surface and induces fibrin-selective clot lysis. Clinical results have shown that prourokinase is a safe and efficient...

Thrombolytic therapy has not only been used as a routine approach in treatment of acute my-ocardial infarction, but also been used in other thromboembolic diseases, such as acute ischaemic stroke, pulmonary embolism, acute peripheral arterial thrombosis and so on. Prourokinase is the single-chain precursor of two-chain urokinase. It activates plasminogen preferentially at the fibrin surface and induces fibrin-selective clot lysis. Clinical results have shown that prourokinase is a safe and efficient thrombolytic agent, and can exhibite synergistic effects when it is used combined with t-PA, streptokinase or urokinase. This article will review its characteristics, structure and functions, pharma-cokinetics and its clinical results.

溶栓疗法不仅已被常规地用于急性心肌梗死的治疗,而且也已用于其它血栓病的治疗中,如急性缺血性脑血栓、肺栓塞、急性周围动脉血栓等。尿激酶原是双链尿激酶的单链前体,它主要激活纤维蛋白表面的纤溶蛋白原,所以具有选择性溶栓作用。临床结果表明它是一种安全有效的溶栓药物,与t-PA、链激酶或尿激酶伍用均有协同作用。本文综述它了的特性、结构与功能,以及它的药代动力学和临床的治疗效果。

Objective:To obtain a reliable assessment of the separate effects on mortality and on disability in survivors of AcuteStroke.Methods:The Chinese Acute Stroke Trial(CAST) was a large randomized, placeboontrolled trial of the effects in hospital of aspirin treatment 160 mg per day started with in 48 h of the onset of suspected acute ischaemic stroke and continuedin hospital for up to 4 weeks.Results: There was a significant 14.0 % (s=7.0) proportional reduction in mortality[343(3. 3 % ) deaths among aspiringroup...

Objective:To obtain a reliable assessment of the separate effects on mortality and on disability in survivors of AcuteStroke.Methods:The Chinese Acute Stroke Trial(CAST) was a large randomized, placeboontrolled trial of the effects in hospital of aspirin treatment 160 mg per day started with in 48 h of the onset of suspected acute ischaemic stroke and continuedin hospital for up to 4 weeks.Results: There was a significant 14.0 % (s=7.0) proportional reduction in mortality[343(3. 3 % ) deaths among aspiringroup vs 398 (3. 9 % ) deaths among placebo group, p=0. 04]. There were significantly fewer recurrent ischaemic strokes inthe aspirin group than in the placebo group[167 (1. 6 % )vs 215 (2. 1% ),p=0. 01],slightly more haemorrhagic strokes[115(1. 1 %) vs 93(0. 9% ),P>0. 1].Conclusion:The present study shows that aspirin started early in hospital produces a significant reduction in mortalityand recurrent stroke during the treatment period,with perhaps slightly less likelihood of functional impairment among thosedischarged alive.

目的:探讨急性缺血性脑卒中早期抗血小板治疗,对降低病人病死率、改善机体残疾率的临床疗效。本试验简称CAST临床试验。方法:采取多中心、随机、双盲治疗。对发病48小时内的急性缺血性脑卒中,经头颅计算机断层摄影术(CT)或临床检查基本排除出血性脑卒中即可入选。每日口服阿司匹林160mg或安慰剂4周。结果:自1993年11月至1997年4月全国413家医院共入选21106例病人。治疗期间阿司匹林组死亡343例,较对照组(死亡398例)下降14.0%(P=0.04)。再发缺血性脑卒中阿司匹林组显著低于对照组(1.6%比2.1%,P=0.01)。出血性脑卒中的发生,阿司匹林组较对照组略有增加,但差别不显著(1.1%比0.9%,P>0.1)。结论:本项研究显示,对急性缺血性脑卒中病人进行早期抗血小板治疗,可显著降低住院期间死亡率及再发脑卒中发生率,并在一定程度上促进病人的功能康复。

Objectives To assess the effect of different thrombolytic agents, and different regimens in acute ischaemic stroke. Methods A systematic review of all the relevant randomized controlled trials (RCTs) was performed. RCTs were i-dentified from the Cochrane Stroke Group trials register, Embase (1980 to 1997), handsearching Japanese and Chinese journals, and personal contact with pharmaceutical companies. We included randomised and quasi-randomised trials in patients with confirmed acute ischaemic...

Objectives To assess the effect of different thrombolytic agents, and different regimens in acute ischaemic stroke. Methods A systematic review of all the relevant randomized controlled trials (RCTs) was performed. RCTs were i-dentified from the Cochrane Stroke Group trials register, Embase (1980 to 1997), handsearching Japanese and Chinese journals, and personal contact with pharmaceutical companies. We included randomised and quasi-randomised trials in patients with confirmed acute ischaemic stroke comparing different doses of a thrombolytic agent, or different thrombolytic agent, or the same agent given by different routes.Results Eight trials involving 1 334 patients were included. Concealment of allocation was generally adequate. All the trials were conducted in Japan. Different doses (of tissue plasminogen activator or urokinase) were compared in six trials. Different agents (tissue plasminogen activator versus urokinase,or tissue-cultured urokinase versus conventional urokinase) were compared in three trials. Few data were available for functional outcomes. A higher dose of thrombolytic therapy was associated with a five-fold increase in fatal intracranial haemorrhages (odds ratio 5.02, 95% confidence interval 1.56 to 16.18). There was a non-significant trend towards more early deaths or clinically significant intracranial haemorrhages in higher dose guoup. No difference in late deaths or extra-cranial haemorrhages was shown between low and higher doses. However, very few of these events occurred. No difference was shown between the different thrombolytic agents tested. Conclusions There is not enough evidence to conclude whether lower doses of thrombolytic agents might be safer or more effective than higher doses in acute ischaemic stroke. It is not possible to conclude whether one agent might be better than another, or which route of administration might be best.

目的 评价不同药物、剂量、给药途径(静脉或动脉)的溶栓疗法治疗急性缺血性脑卒中的疗效和安全性。方法应用国际Cochrane协作网的系统评价方法对全世界关于不同药物、剂量、给药途径溶栓疗法治疗急性缺血性脑卒中的随机和半随机对照试验进行了系统评价。结果 共收集到14个已完成的随机对照试验,8个试验(共包括1334例病人)符合纳入标准,其中6个试验比较了不同剂量的t-PA和尿激酶的疗效,3个试验比较了不同药物的疗效。高剂量溶栓治疗组致死性颅内出血事件较低剂量溶栓治疗组显著增加(OR 5.02,95%CI 1.56-16.18),高剂量溶栓治疗组呈现早期死亡或严重出血增加的趋势但未达到统计学意义,远期死亡或颅外出血在高、低剂量组之间无明显差异,不同溶栓药物效果的比较无显著差异。结论 目前尚无足够证据证明是否低剂最溶栓药物治疗急性缺血性脑卒中比高剂量更为安全和有效,亦不能作出一种溶栓药物比另一种更好或哪种给药途径更佳的结论。本系统评价的更新版将于近期在Cochrane图书馆发表。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关acute ischaemic stroke的内容
在知识搜索中查有关acute ischaemic stroke的内容
在数字搜索中查有关acute ischaemic stroke的内容
在概念知识元中查有关acute ischaemic stroke的内容
在学术趋势中查有关acute ischaemic stroke的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社